Intake of Vitamin K Antagonists and Worsening of Cardiac and Vascular Disease: Results From the Population-Based Gutenberg Health Study

Lisa Eggebrecht, Juergen H. Prochaska, Andreas Schulz, Natalie Arnold, Claus Juenger, Sebastian Goebel, Dagmar Laubert-Reh, Harald Binder, Manfred E. Beutel, Nobert Pfeiffer, Stefan Blankenberg, Karl J. Lackner, Henri M. Spronk, Hugo ten Cate, Thomas Muenzel, Philipp S. Wild*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

10 Citations (Web of Science)

Abstract

Background-Preclinical data have indicated a link between use of vitamin K antagonists (VKA) and detrimental effects on vascular structure and function. The objective of the present study was to determine the relationship between VKA intake and different phenotypes of subclinical cardiovascular disease in the population.

Methods and Results-Clinical and laboratory data, as well as medical-technical examinations were assessed from 15 010 individuals aged 35 to 74 years during a highly standardized 5-hour visit at the study center of the population-based Gutenberg Health Study. In total, the study sample comprised 287 VKA users and 14 564 VKA nonusers. Multivariable analysis revealed an independent association between VKA intake and stiffness index (beta=+2.54 m/s; [0.41/4.66]; P=0.019), ankle-brachial index (beta=-0.03; [- 0.04/-0.01]; P

Conclusions-These data demonstrate negative effects of VKA on vascular and cardiac phenotypes of subclinical cardiovascular disease, indicating a possible influence on long-term disease development. These findings may be clinically relevant for the provision of individually tailored antithrombotic therapy.

Original languageEnglish
Article number008650
Number of pages25
JournalJournal of the American Heart Association
Volume7
Issue number17
DOIs
Publication statusPublished - 4 Sep 2018

Keywords

  • cardiovascular disease
  • oral anticoagulation
  • pharmacogenomic variants
  • vitamin K antagonists
  • MATRIX GLA-PROTEIN
  • ORAL ANTICOAGULANT
  • CALCIFICATION
  • WARFARIN
  • PROGRESSION
  • ARTERIAL
  • THERAPY
  • RISK

Cite this